Morgan Stanley analyst Jeffrey Hung raised the firm’s price target on PTC Therapeutics to $45 from $32 and keeps an Equal Weight rating on the shares. The firm’s estimates are “slightly” above consensus on Translarna net product revenues and in line on Emflaza net product revenue, the analyst tells investors in a preview note. On the call, the firm would listen for details related to the CHMP re-examination process and updates on the submission of the additional information requested by the FDA related to the NDA re-submission, the analyst added.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PTCT:
- Biotech Alert: Searches spiking for these stocks today
- PTC Therapeutics reports ‘positive’ results from LT studies, says Baird
- PTC Therapeutics provides update on vatiquinone Friedreich ataxia program
- PTC Therapeutics announces FDA acceptance for filing of NDA for sepiapterin
- PTC Therapeutics’ fast track designation for PTC518 ‘positive,’ says Baird